Metraipolis › archive › dc_d373c181ada3
Cost-effectiveness of dengue vaccination in Puerto Rico — Europe PMC PMID:34310614
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/34310614
- DOI
- 10.1371/journal.pntd.0009606
- License (as archived)
- CC0-1.0
- Archived
- 2026-10-07T22:12:39.584Z
- SHA-256 of the archived text
99d6bef579596ff09d81acfe0e67408a2faab5909e84fe2e4b9be2417a97fb17- Stable URL of this page
https://metraipolis.com/documento/dc_d373c181ada3
How to cite
Cost-effectiveness of dengue vaccination in Puerto Rico — Europe PMC PMID:34310614 — Europe PMC (en), https://europepmc.org/article/MED/34310614 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_d373c181ada3 (Metraipolis archive dc_d373c181ada3, sha256 99d6bef579596ff09d81acfe0e67408a2faab5909e84fe2e4b9be2417a97fb17)
BibTeX
@misc{dcd373c181ada3,
title = {Cost-effectiveness of dengue vaccination in Puerto Rico — Europe PMC PMID:34310614},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/34310614},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_d373c181ada3; sha256 99d6bef579596ff09d81acfe0e67408a2faab5909e84fe2e4b9be2417a97fb17},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/34310614. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
An effective and widely used vaccine could reduce the burden of dengue virus (DENV) around the world. DENV is endemic in Puerto Rico, where the dengue vaccine CYD-TDV is currently under consideration as a control measure. CYD-TDV has demonstrated efficacy in clinical trials in vaccinees who had prior dengue virus infection. However, in vaccinees who had no prior dengue virus infection, the vaccine had a modestly elevated risk of hospitalization and severe disease. The WHO therefore recommended a strategy of pre-vaccination screening and vaccination of seropositive persons. To estimate the cost-effectiveness and benefits of this intervention (i.e., screening and vaccination of seropositive persons) in Puerto Rico, we simulated 10 years of the intervention in 9-year-olds using an agent-based model. Across the entire population, we found that 5.5% (4.6%-6.3%) of dengue hospitalizations could be averted. However, we also found that 0.057 (0.045-0.073) additional hospitalizations could occur for every 1,000 people in Puerto Rico due to DENV-naïve children who were vaccinated following a false-positive test results for prior exposure. The ratio of the averted hospitalizations among all vaccinees to additional hospitalizations among DENV-naïve vaccinees was estimated to be 19 (13-24). At a base case cost of vaccination of 382 USD, we found an incremental cost-effectiveness ratio of 122,000 USD per QALY gained. Our estimates can provide information for considerations to introduce the CYD-TDV vaccine in Puerto Rico. Tema degli esploratori: agenti e intelligenza artificiale (ricerca Europe PMC «agent-based model», solo open access). Pubblicazione: PLoS neglected tropical diseases, 2021 (prima pubblicazione 2021-07-26). Identificativi: PMID 34310614 · PMCID PMC8341694 · DOI 10.1371/journal.pntd.0009606. Descrittori MeSH principali: Cost-Benefit Analysis. Pagina: https://europepmc.org/article/MED/34310614 — https://doi.org/10.1371/journal.pntd.0009606. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-10-07T21:53:41.631Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.